GLP-1 Receptor Research: Cloning, Signalling and the Published Evidence Base

The GLP-1 receptor from its 1992 cloning to the trials that defined it: expression, signalling, the clearance problem and the published evidence.

By Published Updated

The glucagon-like peptide-1 receptor is the most extensively studied target in metabolic peptide pharmacology, and it is the reference point against which every other receptor in this library's metabolic section is described. Almost everything the field now does at the GIP, glucagon and amylin receptors is an argument about what to add to, or substitute for, activity at this one.

This article sets out what the receptor is, how it was found, what is established about its signalling and distribution, and what the published research at each level of evidence reports. It describes research. It contains no guidance of any kind on handling any material.

What the receptor is

The GLP-1 receptor is a class B1 — secretin-like — G protein-coupled receptor. It was identified by expression cloning from pancreatic beta cells in 1992, which is the paper that defines the target and the starting point for everything that followed [1]. Class B1 receptors are a small family characterised by a large extracellular N-terminal domain that binds the C-terminal portion of a peptide ligand, with the ligand's N-terminus then engaging the transmembrane core to produce activation. The other members relevant here are the GIP receptor, the glucagon receptor, the growth hormone-releasing hormone receptor and the calcitonin receptor.

The receptor couples through Gs to adenylate cyclase, raising intracellular cyclic AMP. That is its canonical signalling route and the one on which the pharmacology of every GLP-1 receptor agonist rests [3].

Its physiology was reviewed comprehensively in 2007, in the same year as a parallel review of both incretin hormones together, and those two reviews remain the standard reference account of the system [3, 2]. The mechanisms and the therapeutic application of GLP-1 were reviewed again a decade later, after the analogue programmes had matured [6].

Where it is expressed, and what it does there

The receptor's distribution explains why a single target produces effects in several apparently unrelated systems.

Pancreatic islet cells. Activation modulates insulin secretion in a glucose-dependent manner — the defining property of an incretin, and the reason this receptor became a diabetes target rather than a general one. Glucose dependence is what distinguishes it from insulin secretagogues that act regardless of glucose [3].

The central nervous system. Receptors at several sites participate in the regulation of food intake. The anatomy here is more specific than it is often described as being, and the rodent work in the animal section below is the clearest published account of it.

The gastrointestinal tract. Activation slows gastric emptying, which contributes both to glycaemic effects and to the gastrointestinal adverse events that dominate the tolerability profile of every agonist at this receptor [2].

Suppression of glucagon secretion. A distinct effect from the insulin one, and part of the reason the GLP-1 arm can offset glucagon receptor agonism in a multi-agonist molecule.

The endogenous ligand and the problem it creates

Native GLP-1 is released from enteroendocrine L cells of the gut in response to nutrient intake. As a drug it would be useless, and for a reason that has nothing to do with the receptor: dipeptidyl peptidase-4 cleaves it within minutes, and what survives is cleared renally almost as fast.

Every analogue in this family is, first and foremost, a solution to that clearance problem. The design work that produced the most-studied of them is unusually explicit about the trade involved: receptor affinity was deliberately reduced — semaglutide's affinity at the GLP-1 receptor was measured at 0.38 ± 0.06 nM, approximately three-fold weaker than the once-daily analogue that preceded it — in exchange for substantially higher affinity for serum albumin [4].

That is the general pattern of the field, and it is worth stating plainly because it inverts the usual intuition. The molecules that dominate this receptor's pharmacology are not the ones that bind it hardest. They are the ones that stay in plasma longest.

What the cell-based and structural research establishes

In vitro research

The receptor-level literature establishes three things that constrain how agonists at this target behave.

The receptor is a single, dedicated gene product. Unlike the amylin receptors, which are assembled from a calcitonin receptor and an accessory protein, the GLP-1 receptor is one protein encoded by one gene, cloned in 1992 [1]. There is no accessory-protein family creating receptor subtypes with different pharmacology, which is why "GLP-1 receptor agonism" names a single activity rather than a distribution of activities.

Affinity and duration are separable design levers. The discovery characterisation of semaglutide separates them explicitly: amino acid substitutions at positions 8 and 34 secure stability against enzymatic degradation, while the fatty acid moiety and the chemistry linking it to the peptide secure albumin affinity, and the two had to be optimised together [4].

Sequence homology across the family makes multi-agonism possible. GLP-1, GIP and glucagon belong to one peptide superfamily with substantial sequence homology, and their receptors have overlapping recognition requirements. That is the structural fact a dual or triple agonist exploits: tirzepatide is built on a GIP backbone engineered to acquire GLP-1 receptor activity [7], and retatrutide is a single chain engaging all three [13].

These are observations in cell-based assays and cell-free chemistry. Potency at a cloned receptor in a transfected cell line is not a proportional predictor of effect in tissue, and the albumin binding that defines this family's pharmacokinetics is absent from the assay entirely.

What the animal research establishes about where the receptor is engaged

Animal research

The single most informative rodent study for this receptor asked a question the clinical trials cannot: where in the body does a long-acting agonist actually act?

In rats, semaglutide did not cross the blood-brain barrier. It nevertheless reached the brainstem, the septal nucleus and the hypothalamus, interacting with the brain through the circumventricular organs and several sites adjacent to the ventricles — that is, through the places where the barrier is anatomically incomplete rather than through the barrier itself [9].

Mapping the consequences, the authors found central c-Fos activation in ten brain areas: hindbrain regions the compound reached directly, and secondary regions with no direct receptor interaction, among them the lateral parabrachial nucleus. Automated analysis of compound access, c-Fos activity, receptor distribution and brain connectivity pointed to neurons in the lateral parabrachial nucleus. Transcriptomic analysis of microdissected regions showed upregulation of prolactin-releasing hormone and tyrosine hydroxylase in the area postrema [9].

Behaviourally, the rodents showed modified food preference and reduced food intake, with body-mass reduction occurring without a decrease in whole-body metabolic rate [9]. That last clause is the direct preclinical contrast with glucagon receptor agonism, where an increase in metabolic rate is the reported contribution [13].

The pharmacokinetic work sits alongside this. In mini-pigs, plasma half-life after intravenous administration was 46.1 hours, and mean residence time after subcutaneous administration was 63.6 hours — the figures that justified a once-weekly schedule in the human studies that followed [4].

Findings described in this section were observed in animals. Rodent and porcine models are standard preclinical tools, and nothing in them establishes anything about humans.

What the human research at this receptor reports

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

This receptor has the deepest clinical evidence base of any target in this library, and — unusually for this field — a substantial part of it consists of outcome trials rather than surrogate endpoints.

Cardiovascular outcomes in type 2 diabetes. SUSTAIN-6 randomised 3,297 participants with type 2 diabetes on a standard-care regimen. The composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.6% against 8.9% for placebo over 104 weeks, hazard ratio 0.74, 95% CI 0.58 to 0.95. Rates of retinopathy complications were significantly higher, hazard ratio 1.76, 95% CI 1.11 to 2.78 — an unexpected finding that remains the most-discussed result of the trial [5]. A separate trial examined cardiovascular safety of an oral formulation [8].

Cardiovascular outcomes without diabetes. SELECT randomised 17,604 participants aged 45 or older with preexisting cardiovascular disease and a body-mass index of 27 or greater, with no history of diabetes. The primary composite occurred in 6.5% against 8.0%, hazard ratio 0.80, 95% CI 0.72 to 0.90 [14, 19]. Adverse events leading to permanent discontinuation occurred in 16.6% against 8.2%.

Kidney outcomes. FLOW randomised 3,533 participants with type 2 diabetes and chronic kidney disease. The composite of kidney failure, at least a 50% reduction in estimated glomerular filtration rate, or death from kidney-related or cardiovascular causes was 24% lower — hazard ratio 0.76, 95% CI 0.66 to 0.88. The trial was stopped early at a prespecified interim analysis, which tends to produce larger effect estimates than a trial run to completion [15, 20].

Liver histology. ESSENCE reported a planned interim analysis in the first 800 of 1,197 participants with biopsy-defined metabolic dysfunction-associated steatohepatitis and fibrosis stage 2 or 3. Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% against 34.3% for placebo, and reduction in fibrosis without worsening of steatohepatitis in 36.8% against 22.4% [17]. The clinical-outcome phase of that trial has not reported.

Anthropometric endpoints. STEP 1 randomised 1,961 adults without diabetes and reported mean change in body weight at 68 weeks of −14.9% against −2.4% for placebo [10]; STEP 2 examined the same regimen in participants who also had type 2 diabetes, where the change was smaller [11].

What runs through all of it. Gastrointestinal adverse events dominate every trial's adverse-event table, are mostly mild to moderate, cluster during escalation, and are the leading cause of discontinuation. That pattern is consistent enough across the programme to be regarded as a property of engaging this receptor rather than of any one molecule.

Where this receptor sits in multi-agonist design

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Every multi-agonist in this receptor family includes the GLP-1 arm. That is not a coincidence of history: it is the arm with the demonstrated clinical-outcome record, and it is the arm that holds glucose in check when a glucagon receptor arm is added.

Two randomised head-to-head trials compared a GIP/GLP-1 dual agonist with a single-receptor GLP-1 agonist. SURPASS-2 randomised 1,879 participants with type 2 diabetes on metformin, with glycated haemoglobin change at 40 weeks as the primary endpoint and semaglutide 1 mg as the comparator [12]. SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes to the maximum tolerated amount of each compound over 72 weeks [18]. Both were open-label and sponsored by the manufacturer of one of the two compounds, and neither was an outcome trial.

No comparable head-to-head exists between a triple agonist and a single-receptor agonist. Published systematic analyses of approved incretin mimetics are explicit that indirect comparison across separate placebo-controlled trials rests on assumptions that head-to-head randomisation does not require [16].

What remains unsettled

How much of the outcome effect is attributable to change in body mass. SELECT enrolled a secondary-prevention population and the trial does not separate how much of its cardiovascular effect follows from anthropometric change and how much from anything else [14].

The retinopathy signal. It appeared unexpectedly in SUSTAIN-6 and has not been resolved by the trials that followed [5].

Whether the receptor's central effects can be separated from its gastrointestinal ones. The rodent anatomy suggests the central and peripheral actions engage partly distinct routes [9], but no clinical strategy for separating them has been demonstrated.

All the research described here studied pharmaceutical material, manufactured to a regulatory standard, administered under registered protocols in defined populations under clinical supervision. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Frequently Asked Questions

What is the GLP-1 receptor?
A class B1, secretin-like G protein-coupled receptor, identified by expression cloning from pancreatic beta cells in 1992 [1]. It couples through Gs to raise intracellular cyclic AMP, and it is a single dedicated gene product rather than an assembled complex [3].
Where is the GLP-1 receptor expressed?
On pancreatic islet cells, where activation modulates glucose-dependent insulin secretion; at sites in the central nervous system involved in the regulation of food intake; and in the gastrointestinal tract, where activation slows gastric emptying [3, 2]. Rodent work mapping where a long-acting agonist reaches the brain found access through the circumventricular organs rather than across the blood-brain barrier [9].
Why do GLP-1 analogues need chemical modification?
Because native GLP-1 is cleared within minutes. Dipeptidyl peptidase-4 cleaves it and the remainder is cleared renally almost as quickly, so every analogue in the family is first a solution to duration rather than to potency. The most-studied of them deliberately traded receptor affinity — approximately three-fold weaker than its predecessor — for much higher albumin affinity [4].
What clinical outcomes have been reported at this receptor?
Cardiovascular composites in type 2 diabetes, hazard ratio 0.74 [5]; cardiovascular composites in cardiovascular disease without diabetes, hazard ratio 0.80 [14]; a composite kidney outcome, hazard ratio 0.76, in a trial stopped early at interim [15]; and histological endpoints in steatohepatitis at a planned interim [17]. This is the only receptor in this library with a substantial outcome-trial record.
Why do GLP-1 receptor agonists cause gastrointestinal adverse events?
Activation of the receptor slows gastric emptying, and gastrointestinal events dominate the adverse-event table of every trial of every agonist at this target, mostly mild to moderate, clustering during escalation and leading discontinuations [2, 10]. The consistency across compounds suggests a property of the receptor rather than of any one molecule.
Do multi-agonists still need the GLP-1 arm?
Every published multi-agonist in this receptor family includes it. It is the arm with the demonstrated outcome record, and in a molecule that also engages the glucagon receptor it is part of what holds glucose in check [13].
Has a dual agonist been compared with a single-receptor GLP-1 agonist?
Twice, both open-label and both sponsored by the manufacturer of one of the two compounds: SURPASS-2 in type 2 diabetes over 40 weeks [12] and SURMOUNT-5 in obesity without diabetes over 72 weeks [18]. Neither was an outcome trial. No equivalent comparison exists for a triple agonist.

References

  1. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proceedings of the National Academy of Sciences of the United States of America; 1992. PMID 1326760 doi:10.1073/pnas.89.18.8641
  2. Biology of incretins: GLP-1 and GIP Gastroenterology; 2007. PMID 17498508 doi:10.1053/j.gastro.2007.03.054
  3. The physiology of glucagon-like peptide 1 Physiological Reviews; 2007. PMID 17928588 doi:10.1152/physrev.00034.2006
  4. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of Medicinal Chemistry; 2015. PMID 26308095 doi:10.1021/acs.jmedchem.5b00726
  5. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes The New England Journal of Medicine; 2016. PMID 27633186 doi:10.1056/NEJMoa1607141
  6. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell Metabolism; 2018. PMID 29617641 doi:10.1016/j.cmet.2018.03.001
  7. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Molecular Metabolism; 2018. PMID 30473097 doi:10.1016/j.molmet.2018.09.009
  8. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes The New England Journal of Medicine; 2019. PMID 31185157 doi:10.1056/NEJMoa1901118
  9. Semaglutide lowers body weight in rodents via distributed neural pathways JCI Insight; 2020. PMID 32213703 doi:10.1172/jci.insight.133429
  10. Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine; 2021. PMID 33567185 doi:10.1056/NEJMoa2032183
  11. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial The Lancet; 2021. PMID 33667417 doi:10.1016/S0140-6736(21)00213-0
  12. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine; 2021. PMID 34170647 doi:10.1056/NEJMoa2107519
  13. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism; 2022. PMID 35985340 doi:10.1016/j.cmet.2022.07.013
  14. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes The New England Journal of Medicine; 2023. PMID 37952131 doi:10.1056/NEJMoa2307563
  15. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England Journal of Medicine; 2024. PMID 38785209 doi:10.1056/NEJMoa2403347
  16. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes, Obesity and Metabolism; 2025. PMID 40212008 doi:10.1111/dom.16398
  17. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis The New England Journal of Medicine; 2025. PMID 40305708 doi:10.1056/NEJMoa2413258
  18. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine; 2025. PMID 40353578 doi:10.1056/NEJMoa2416394
  19. Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity. NCT03574597
  20. A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease. NCT03819153

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.